A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Clinical trial NCT04675983 · TERMINATED

Trial details

NCT number: NCT04675983
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric Adenocarcinoma

Start date: 2021-03-10
Primary completion: 2023-02-12
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.